Norwalk, CT - November 14, 2024 – LifeSpan Vision Ventures, an investment firm specializing in the aging and longevity space, today announced an investment in Algen Biotechnologies.
Algen Biotechnologies combines CRISPR-based gene modulation with AI to reverse engineer disease biology and identify new therapeutics. Originating from the lab of Nobel laureate Jennifer Doudna, Algen uses two proprietary platforms: AlgenCRISPR, a flexible gene modulation system, and AlgenBrain, an AI-driven system that analyzes vast multi-omics data to guide target and compound selection. These platforms map disease pathways at the single-cell level, uncovering potential treatments. Algen’s pipeline includes multiple programs across oncology, immunology, and metabolic disorders, with a lead anti-cancer agent nearing clinical trials.
LifeSpan Vision Ventures’ Founding Partner, Andrew Worden, commented “We are excited to support Algen’s talented team of biotech pioneers as they fuse state-of-the-art deep learning models and industrialised single cell CRISPR gene-modulation to decode cellular signalling networks that drive a wide range of age-related diseases.”
Chun-Hao Huang, Ph.D. CEO and co-founder of Algen, stated, “We are delighted to welcome Lifespan Vision Ventures as an investor in Algen. With the support from Lifespan, we are accelerating our CRISPR-driven data creation and deep learning at scale to find new treatments for diseases with unmet medical need for healthspan extension.”
About Algen Biotechnologies
Algen is a platform therapeutics and drug discovery company using the world’s leading CRISPR and AI to uncover disease-driving RNA messages to find treatments for cancer, inflammation and metabolic diseases. Spun out from Nobel Laureate Professor Jennifer Doudna's Lab, Algen aims to develop the world’s smartest drug discovery decision platform and data universe to create next-generation therapeutics. Algen has its internal drug development pipeline and partners with several leading pharmaceutical companies on its flagship next-generation CRISPR-based platform.
For more information, visit: www.algenbio.com
About LifeSpan Vision Ventures
LifeSpan Vision Ventures is a forward-thinking venture capital firm specializing in investments within the aging and longevity space. Our mission is to support and accelerate the development of innovative therapies that extend healthspan, improve the quality of life for individuals as they age, and address age-related challenges. Through strategic partnerships and investments, we aim to shape a future where aging is met with vitality, resilience, and endless possibilities.
Contact: Harry Robb, Analyst: harry.robb@lifespanvision.com
Comments